Immune Cells get Cancer-Fighting Boost From Nanomaterials
News Aug 18, 2014
Scientists at Yale University have developed a novel cancer immunotherapy that rapidly grows and enhances a patient’s immune cells outside the body using carbon nanotube-polymer composites; the immune cells can then be injected back into a patient’s blood to boost the immune response or fight cancer.
According to the researchers, the topography of the carbon nanotubes (CNTs) enhances interactions between cells and long-term cultures, providing a fast and effective stimulation of the cytotoxic T cells that are important for eradicating cancer.
The researchers modified the CNTs by chemically binding them to polymer nanoparticles that held Interleukin-2, a cell signaling protein that encourages T cell growth and proliferation. Additionally, in order to mimic the body’s methods for stimulating cytotoxic T cell proliferation, the scientists seeded the surfaces of the CNTs with molecules that signaled which of the patient’s cells were foreign or toxic and should be attacked.
Over the span of 14 days, the number of T cells cultured on the composite nanosystem expanded by a factor of 200, according to the researchers. Also, the method required 1,000 times less Interleukin-2 than conventional culture conditions. A magnet was used to separate the CNT-polymer composites from the T cells prior to injection.
“In repressing the body’s immune response, tumors are like a castle with a moat around it,” says Tarek Fahmy, an associate professor of biomedical engineering and the study’s principal investigator. “Our method recruits significantly more cells to the battle and arms them to become superkillers.”
According to Fahmy, previous procedures for boosting antigen-specific T cells required exposing the patient’s harvested immune cells to other cells that stimulate activation and proliferation, a costly procedure that risks an adverse reaction to foreign cells. The Yale team’s use of magnetic CNT-polymer composites eliminates that risk by using simple, inexpensive magnets.
“Modulatory nanotechnologies can present unique opportunities for promising new therapies such as T cell immunotherapy,” says Tarek Fadel, lead author of the research and a Yale postdoc who is currently a staff scientist with the National Nanotechnology Coordination Office. “Engineers are progressing toward the design of the next generations of nanomaterials, allowing for further breakthrough in many fields, including cancer research.”
Two additional Yale engineering faculty contributed to this article: Gary Haller, the Henry Prentiss Becton Professor of Engineering and Applied Science and a professor of chemistry; and Lisa Pfefferle, the C. Baldwin Sawyer Professor of Chemical and Environmental Engineering. Other authors include Fiona Sharp, Nalini Vudattu, Ragy Ragheb, Justin Garyu, Dongin Kim, Enping Hong, Nan Li, Sune Justesen, and Kevan Herold.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.